Frontiers in Oncology最新文献

{"title":"Endometrial cancer molecular classification: research advances and clinical application.","authors":"Ya Liu, Yueying Li, Liping Zhang","doi":"10.3389/fonc.2026.1947939","DOIUrl":"https://doi.org/10.3389/fonc.2026.1947939","url":null,"abstract":"<p><p>As research in molecular biology continues to advance, the classification of endometrial cancer has gradually shifted from traditional histology toward risk stratification based on the integration of molecular subtyping with clinicopathologic factors. Molecular subtyping has not only transformed our understanding of the biological heterogeneity of endometrial cancer but also provided new evidence for prognostic assessment and treatment selection. However, the maturity of clinical evidence and the translational therapeutic value vary across molecular subtypes. This review systematically summarizes the molecular characteristics and clinical significance of the POLE ultramutated(POLE-mut)subtype, mismatch repair deficient (dMMR) subtype, p53 abnormal (p53-abn) subtype, and no specific molecular profile (NSMP) subtype, with a focus on evaluating whether different molecular features can be further translated from risk stratification into specific treatment decisions. Centering on key issues such as de-escalated therapy for the POLE-mut subtype, the predictive value of immunotherapy for the dMMR subtype, intensified therapy for the p53-abn subtype, and further risk stratification of the NSMP subtype, this review analyzes the clinical basis and limitations of existing evidence and further discusses the challenges that tumors with multiple molecular features pose for classification and treatment decision making. Building on this, the paper compares how major international guidelines integrate molecular information with clinical and pathologic factors and analyzes real world implementation barriers such as testing standardization, result interpretation, and healthcare accessibility. Finally, it outlines the potential value of emerging technologies, including liquid biopsy, artificial intelligence, and multiomics, in dynamic risk assessment and precision therapy. This review aims to trace the continuum of evidence from molecular discovery to clinical action, clarifying which clinical decisions can be supported by existing molecular markers and identifying questions that current evidence cannot yet answer, thereby providing guidance for the precise application and clinical translation of molecular subtyping in endometrial cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1947939"},"PeriodicalIF":3.4,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing combined with artificial intelligence to uncover immunotherapy biomarkers and decipher drug resistance mechanisms in glioblastoma.","authors":"Tao Fu, Mengwan Hu, Xian Wu","doi":"10.3389/fonc.2026.1970165","DOIUrl":"https://doi.org/10.3389/fonc.2026.1970165","url":null,"abstract":"<p><p>Glioblastoma represents the most aggressive primary malignant tumor of the central nervous system, characterized by extensive intratumoral heterogeneity, profound immunosuppression, therapeutic resistance, and poor clinical outcomes. Although immunotherapy has revolutionized cancer treatment, its clinical efficacy in GBM remains limited, largely due to the complexity of the tumor ecosystem and the lack of validated predictive biomarkers. Recent advances in single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and artificial intelligence (AI)-based computational approaches have provided unprecedented opportunities to decipher tumor heterogeneity and identify clinically actionable biomarkers. This mini-review integrates studies related to scRNA-seq and its combination technology, further elaborating on the tumor plasticity, immune suppression, and metabolic-epigenetic reprogramming mechanisms of GBM. The article systematically summarizes the complete analysis process of integrating single-cell multi-omics data by AI and highlights the application value of AI in validating biomarkers. The above research ideas are expected to overcome clinical resistance problems, optimize patient stratification schemes, and enhance the efficacy of immunotherapy, providing theoretical support for developing highly stable prognostic biomarkers and achieving individualized precise immunotherapy for glioblastoma.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1970165"},"PeriodicalIF":3.4,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149227669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging innovative immunotherapies in malignant ascites: current landscape, challenges and perspectives.","authors":"Xian Liu, Xiaobo Peng, Xiaoxiao Wu, Yue Wu, Tong Yin, Jingyu Liu, Huawei Xu, Xianbao Zhan","doi":"10.3389/fonc.2026.1893803","DOIUrl":"10.3389/fonc.2026.1893803","url":null,"abstract":"<p><p>Malignant ascites is a common, severe complication of advanced solid tumors, driven by multifactorial pathogenesis, including impaired lymphatic drainage, vascular endothelial growth factor-induced vascular hyperpermeability, pro-permeability inflammatory cytokines, and profound peritoneal immunosuppression. Clinically, it correlates with poor prognosis, reduced overall survival, and substantial quality-of-life deterioration. Current treatment remains predominantly palliative: repeated large-volume paracentesis offers transient symptom relief, fails to prevent reaccumulation, and carries procedural risks. Emerging evidence indicates malignant ascites is not merely passive fluid accumulation but an active, immunosuppressive niche shaped by bidirectional crosstalk among tumor cells, stromal components, diverse immune subsets (e.g., regulatory T cells, myeloid-derived suppressor cells, dysfunctional CD8⁺ T cells), and soluble mediators. This narrative review summarizes recent advances in immunomodulatory treatment for malignant ascites, with an emphasis on strategies targeting the ascitic immune microenvironment. Intraperitoneal administration of immune checkpoint inhibitors has shown acceptable safety and preliminary activity in early-phase single-arm trials, although confirmatory data from larger controlled studies are lacking. In randomized trials, the T-cell engager catumaxomab prolonged puncture-free survival, while the bispecific antibody M701 has shown similar benefits in a phase II randomized controlled study; these findings support further investigation of localized T-cell redirection. Preclinical and early-phase clinical studies suggest that intraperitoneal oncolytic viruses can induce immunogenic tumor cell death and T-cell activation, with single-cell analyses indicating remodeling of the ascitic immune microenvironment. Future directions include integrating ascites immune phenotyping, patient-derived organoids for drug sensitivity testing, and machine learning-based decision support to guide personalized immunotherapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1893803"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed epithelial and stromal tumor of the kidney with prominent peritumoral adipose tissue: a case report radiologically mimicking angiomyolipoma with epithelial cysts.","authors":"Chuanchuan Wu, Yang Zhang, Bangwei Che, Jiancheng Zhai, Shenglan Yuan, Linjie Lu, Kai Xiong, Yinqian Li, Kai-Fa Tang","doi":"10.3389/fonc.2026.1918612","DOIUrl":"10.3389/fonc.2026.1918612","url":null,"abstract":"<p><p>Mixed epithelial and stromal tumor of the kidney (MEST) is a rare renal neoplasm with biphasic differentiation comprising epithelial and stromal components. It typically appears as a mixed cystic-solid mass on imaging, and the prognosis is favorable in the vast majority of cases. We report a case of MEST with a prominent fat component on imaging: a 54-year-old woman was admitted with a 1-month history of left flank distension and pain. Contrast-enhanced computed tomography (CT) showed a mixed cystic-solid mass at the lower pole of the left kidney, with a prominent low-attenuation fat-density area surrounding the mass. Preoperatively, the lesion was considered an unusual angiomyolipoma with epithelial cysts (AMLEC). Because the lesion was small, located at the lower pole, and relatively well circumscribed, the patient underwent laparoscopic left partial nephrectomy. Postoperative histopathologic examination confirmed that the left renal mass was benign; however, immunohistochemistry (IHC) demonstrated positivity for EMA and PCK in the epithelial component and for PR and ER in the stromal component, supporting a diagnosis of MEST. The adipose tissue submitted separately with the tumor was located around the tumor and could not be definitively confirmed as an intratumoral component. This case demonstrates that MEST may also exhibit prominent adipose tissue on imaging and illustrates the diagnostic pitfall in which fat-related imaging findings cause MEST to mimic AMLEC, making the early distinction between MEST and cystic change in fat-containing renal tumors challenging.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1918612"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiparametric MRI-based habitat and peritumoral radiomics integrating semi-automated segmentation for preoperative prediction of high-grade prostate cancer: a dual-center study.","authors":"Danni Hua, Luyang Ma, Xiaodong Ji, Lixiang Huang, Yujiao Zhao, Wen Shen","doi":"10.3389/fonc.2026.1937448","DOIUrl":"10.3389/fonc.2026.1937448","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop and validate an interpretable machine learning framework that combines semi-automated segmentation, intratumoral habitats derived from multiparametric MRI (mpMRI), and multiscale peritumoral radiomics to predict high-grade prostate cancer (HGPCa) before surgery.</p><p><strong>Methods: </strong>This retrospective dual-center study involved 274 patients, comprising 208 from Center 1 for development and 66 from Center 2 for external test. The clinical and imaging variables included patient age, serum PSA, fPSA, PSAD, maximum tumor diameter, PI-RADS scores, and anatomical zone distribution (PZ vs. TZ). The development cohort was randomly divided into a training cohort (n = 145) and an internal validation cohort (n = 63). Intratumoral habitats were delineated using semi-automated segmentation and unsupervised K-means clustering, while peritumoral radiomic features were extracted from concentric 1-, 3-, and 5-mm shells. Predictive classifiers were optimized through machine learning algorithms, particularly a multilayer perceptron (MLP) for the habitat signature. A combined clinical-radiomics nomogram was constructed, with SHapley Additive exPlanations (SHAP) employed to enhance model interpretability. Subgroup analyses were performed to assess the discriminative performance of the combined nomogram across the peripheral zone (PZ) and transition zone (TZ).</p><p><strong>Results: </strong>The combined nomogram exhibited superior diagnostic performance, achieving AUCs of 0.914, 0.903, and 0.797 in the training cohort, internal validation cohort, and external test cohort, respectively. The MLP-based habitat model showed good discriminative performance, with AUCs of 0.896, 0.897, and 0.782 across the training cohort, internal validation cohort, and external test cohort, respectively. Among the peritumoral regions, the 5-mm shell demonstrated the best discriminative performance. SHAP analysis identified Habitat 1 Shape Sphericity as the most influential feature. Subgroup analysis demonstrated the discriminatory ability of the combined nomogram in both the PZ (AUC: 0.796) and TZ (AUC: 0.753) subgroups.</p><p><strong>Conclusion: </strong>The integration of semi-automated segmentation-based habitat analysis and peritumoral radiomics provides a promising approach for preoperative risk stratification of prostate cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1937448"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age- and AMH-based prediction of mature oocyte yield in oncofertility is well calibrated overall, but substantial underestimation is more frequent in hematologic malignancies.","authors":"Claudia Massarotti, Sara Stigliani, Paola Scaruffi, Fausta Sozzi, Andrea Amaroli, Paola Anserini","doi":"10.3389/fonc.2026.1940599","DOIUrl":"10.3389/fonc.2026.1940599","url":null,"abstract":"<p><strong>Introduction: </strong>age and ovarian reserve markers are commonly used in clinical practice to predict ovarian response to controlled stimulation for assisted reproductive techniques in infertile patients. In oncofertility, some reports suggest the predictive performance of these markers may be lower in specific subgroups. We evaluated the performance of a prespecified age + log(AMH) model for predicting metaphase-II (MII) oocyte yield in women undergoing oocyte cryopreservation before gonadotoxic treatment.</p><p><strong>Methods: </strong>This retrospective single-center cohort study included consecutive oocyte cryopreservation cycles performed before gonadotoxic treatment between January 2015 and January 2025. MII yield was modelled using negative-binomial regression with age and log-transformed AMH as predictors. Regression coefficients were estimated in the current cohort. Model performance was assessed using calibration measures and patient-level bootstrap internal validation, with all cycles from the same woman kept together during resampling. Analyses were performed overall and by cancer type. Threshold-based underestimation analyses and the incremental value of antral follicle count (AFC) were also explored.</p><p><strong>Results: </strong>A total of 179 oocyte cryopreservation cycles performed in 167 women were included. The model showed good overall calibration using aggregated out-of-bootstrap predictions, with calibration-in-the-large of 0.00 (95% CI -0.08 to 0.09) and calibration slope of 0.98 (95% CI 0.80 to 1.15). Mean prediction error was -0.10 MII (95% CI -0.97 to 0.80), indicating minimal average directional bias. Mean absolute error was 4.12 MII (95% CI 3.53 to 4.76), and root mean squared error was 5.94 MII (95% CI 4.92 to 7.00). Substantial underestimation, defined as observed MII yield exceeding predicted yield by more than 4 MII, was more frequent in hematologic malignancies than in solid tumors (31.8% [14/44] vs 12.6% [17/135]; risk difference +19.2 percentage points, 95% CI + 4.4 to +34.1; Fisher's exact p=0.006). This finding remained consistent in the one-cycle-per-woman sensitivity analysis. Adding AFC did not improve predictive performance in the complete-case analysis.</p><p><strong>Conclusion: </strong>age and AMH are useful tools for counseling regarding the expected mature oocyte yield, including in our subset of oncofertility patients. As we found substantial underestimation of mature oocyte yield to be more frequent in hematologic malignancies, the results should be interpreted cautiously in this subgroup.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1940599"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pretreatment body mass index as a prognostic factor for clinical course and survival in primary surgically treated oral squamous cell carcinoma - a retrospective study.","authors":"Eike Floegel, Leonard Simon Brandenburg, Janek Aaron Arias Romero, Kirstin Vach, Marc Christian Metzger, Rainer Schmelzeisen, Jonas Wüster","doi":"10.3389/fonc.2026.1894543","DOIUrl":"10.3389/fonc.2026.1894543","url":null,"abstract":"<p><strong>Introduction: </strong>In oral squamous cell carcinoma (OSCC), body mass index (BMI) is an available but imperfect marker of nutritional reserve. Evidence on pretreatment BMI in surgery-based European OSCC cohorts remains limited, especially regarding perioperative outcomes. This study evaluated associations of pretreatment BMI with overall survival (OS), recurrence-free survival (RFS), and perioperative outcomes after curative-intent R0 resection.</p><p><strong>Methods: </strong>This retrospective single-center cohort included adult patients with previously untreated primary OSCC, available pretreatment BMI, and curative-intent R0 surgery between 2014 and 2023. BMI was assessed continuously and by World Health Organization (WHO) categories. OS and RFS were analyzed using multivariable Cox regression adjusted for age, sex, pathological T category, nodal status, microvascular free-flap reconstruction, and diabetes mellitus. Perioperative outcomes included red blood cell (RBC) transfusion, RBC units transfused, percutaneous endoscopic gastrostomy (PEG) placement, and intensive care unit (ICU) and hospital length of stay.</p><p><strong>Results: </strong>A total of 274 patients with available pretreatment BMI were included; 116 deaths occurred. Five-year OS ranged from 31.4% in patients classified as underweight to 82.0% in patients with obesity. Higher BMI was associated with lower mortality (HR per 1 kg/m² 0.95, 95% CI 0.91-0.99; p = 0.013), and obesity was associated with improved OS compared with normal weight (HR 0.50, 95% CI 0.26-0.96; p = 0.037). BMI was not significantly associated with RFS after adjustment (HR per 1 kg/m² 0.97, 95% CI 0.93-1.00; p = 0.080). Higher BMI was associated with fewer perioperative RBC transfusions (any transfusion: OR 0.91, 95% CI 0.84-0.98; p = 0.012; number of units: OR 0.89, 95% CI 0.82-0.95; p = 0.001). BMI was not independently associated with PEG placement or hospital length of stay; ICU findings depended on BMI modeling.</p><p><strong>Discussion: </strong>Higher pretreatment BMI was associated with better OS and lower perioperative RBC transfusion requirements, whereas associations with RFS and most other perioperative outcomes were not significant after adjustment. Given the retrospective design and limitations of BMI as a body-composition marker, these findings should be interpreted cautiously. Pretreatment BMI may help identify low-BMI patients warranting early supportive-care assessment.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1894543"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stratification of gastric cancer risk based on family history with cost-effectiveness of opportunistic endoscopic screening: a hospital-based cross-sectional study (SIGES).","authors":"Zhuo-Yu Li, Wen Xiang, Yan Huang, Xin-Zu Chen","doi":"10.3389/fonc.2026.1902158","DOIUrl":"10.3389/fonc.2026.1902158","url":null,"abstract":"<p><strong>Objectives: </strong>The strategy for opportunistic endoscopic screening driven by family history of gastric cancer needs to be optimized in a tailored manner through further risk stratification.</p><p><strong>Methods: </strong>A hospital-based cross-sectional study included health check-up controls and gastric cancer patients at West China Hospital, Sichuan University. Demographic characteristics, comorbidities, family history of malignancies, and serology were analyzed for associations with gastric cancer risk. Associations between family history of gastric cancer and incident gastric cancer risk were assessed, and a rapid cost-effectiveness analysis was performed.</p><p><strong>Results: </strong>In total, 58,218 observations were analyzed, including 619 gastric cancer patients. Family history of gastric cancer was an independent risk factor for gastric cancer (adjusted odds ratio [aOR] = 5.59, 95% CI 3.81-8.20) and was associated with an increased risk of upper digestive tract benign comorbidities (aOR = 1.51, 95% CI 1.09-2.71). For persons with a family history of gastric cancer who were older than 40 years (odds ratio [OR] = 2.36, 95% CI 1.29-4.32), endoscopic screening could be mildly recommended in general practice. Endoscopic screening should be moderately recommended for those with a family history of gastric cancer if they were older than 60 years (OR = 8.90, 95% CI 3.84-20.61) and strongly recommended if they also had upper digestive tract benign comorbidities (OR = 16.78, 95% CI 7.03-40.06), seropositivity for carcinoembryonic antigen (CEA) and/or carbohydrate antigen 19-9 (CA19-9) (OR = 20.77, 95% CI 9.15-47.14), or anemia (OR = 80.11, 95% CI 33.07-194.05). A rapid cost-effectiveness analysis indicated that moderate-to-strong recommendations were preferred, but based on willingness-to-pay considerations, mild-to-strong recommendations had a considerable detection rate for gastric cancer. Sensitivity analysis yielded consistent findings for decision-making.</p><p><strong>Conclusions: </strong>Family history of gastric cancer is an independent risk factor for gastric cancer. Optimized risk stratification based on family history can improve the cost-effectiveness of detecting gastric cancer. The mechanism by which a family history of gastric cancer increases gastric cancer risk and a more tailored family history-driven endoscopic screening strategy require further investigation.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1902158"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global research landscape of ferroptosis in colorectal cancer: a multi-database bibliometric analysis (2017-2025).","authors":"Fengfeng You, Rong Tan, Fengxi Long, Bing Yang, Dongxin Tang","doi":"10.3389/fonc.2026.1918936","DOIUrl":"10.3389/fonc.2026.1918936","url":null,"abstract":"<p><strong>Objective: </strong>Ferroptosis, an iron-dependent form of regulated cell death, has attracted increasing attention in recent years because of its critical roles in tumor progression, therapeutic resistance, and immune regulation. Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide and imposes a substantial mortality burden. This study aimed to systematically analyze the global research landscape, hotspots, and developmental trends of ferroptosis in CRC research from 2017 to 2025.</p><p><strong>Methods: </strong>English-language publications related to ferroptosis and CRC published between January 1, 2017, and December 31, 2025, were retrieved from the Web of Science Core Collection (WoSCC) and Scopus databases. A total of 1, 354 original articles and reviews were included. VOSviewer, CiteSpace, and the bibliometrix package in R were used for bibliometric and visualization analyses to evaluate annual publication trends, country/region and institutional collaboration networks, author contributions, journal distribution, co-cited references, keyword co-occurrence, and thematic evolution.</p><p><strong>Results: </strong>The number of publications in this field increased rapidly after 2020 and peaked in 2025. China ranked first in both publication output and total citations, followed by the United States, and China-United States collaboration constituted the core of the international collaboration network. Central South University was the most productive institution, while journals such as Frontiers in Oncology and Frontiers in Immunology served as major publication platforms. Research hotspots were mainly concentrated on chemotherapy resistance, the tumor immune microenvironment, PANoptosis, prognostic models, non-coding RNAs, gut microbiota, and the regulation of ferroptosis by traditional Chinese medicine and natural products.</p><p><strong>Conclusion: </strong>Ferroptosis has become a rapidly evolving frontier in CRC research. The research focus is gradually shifting from fundamental molecular mechanisms toward translational medical directions, including chemosensitization, combination immunotherapy, reversal of drug resistance, and precise prognostic evaluation. This study provides a systematic reference for understanding the global knowledge structure and future research directions in the field of ferroptosis and CRC.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1918936"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Modulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management.","authors":"Ramazan Tunc, Ilker Ates, Beyza Yılmaz, Alessandro Medoro, Sergio Davinelli, Sibel Suzen, Luciano Saso","doi":"10.3389/fonc.2026.1988777","DOIUrl":"https://doi.org/10.3389/fonc.2026.1988777","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fonc.2025.1701249.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"16 ","pages":"1988777"},"PeriodicalIF":3.4,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}